Drug intelligence / Profile preview

esomeprazole + pantoprazole

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

This is not a fixed-dose combination product but rather two separate proton pump inhibitors (PPIs). Esomeprazole (Nexium) and pantoprazole (Protonix) are individual medications that work by decreasing acid secretion in the stomach through inhibition of the proton pump enzymes. Clinical studies have shown that 40 mg of pantoprazole and 40 mg of esomeprazole are equally effective for healing esophageal lesions and relieving GERD-related symptoms.

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on esomeprazole + pantoprazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on esomeprazole + pantoprazole.

Explore the full profile